New insider activity at Edwards Lifesciences ( (EW) ) has taken place on February 14, 2025.
Director Heisz Leslie Stone recently executed a significant transaction involving Edwards Lifesciences stock, selling a total of 5,739 shares. This sale amounted to a substantial $435,360, reflecting a notable shift in holdings.
Recent Updates on EW stock
In the last 24 hours, Edwards Lifesciences has been the focus of several price target adjustments following its recent Q4 earnings report. Canaccord raised its price target due to a solid Q4 performance and reiterated guidance, although the growth rates for Q1/25 were anticipated to be lower due to fewer selling days. Barclays increased its target, citing strong organic growth and margin improvements, which contributed to an earnings beat and reinforced confidence in the company’s long-term growth prospects. Morgan Stanley also raised its target, emphasizing the importance of the upcoming SAPIEN M3 mitral replacement product launch in the EU in 2025. Piper Sandler adjusted its target after the company posted better-than-expected Q4 results and maintained its 2025 guidance, though they remain cautious about the high-end of the full-year forecast, particularly concerning TAVR. Overall, Edwards Lifesciences’ strategic acquisitions, robust performance in the TMTT segment, and positive outlook for 2025 have driven these price target changes despite some regional and capacity challenges.
More about Edwards Lifesciences
YTD Price Performance: 4.45%
Average Trading Volume: 4,865,108
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $44.72B